Investment in a Corporate Venture - Narrative (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jul. 01, 2018
Schedule of Equity Method Investments [Line Items]
Other long-term liabilities		$ 41,995,000	$ 26,183,000
Investment in equity investee		2,703,000	1,701,000
Retained earnings		696,211,000	611,903,000
Income (loss) from equity method investments		2,402,000	(2,721,000)	$ (3,607,000)
Cost of sales		2,813,071,000	3,004,838,000	2,930,498,000
Intra-entity profits share for unsold products, eliminated in consolidation		3,000,000.0	1,700,000
ASU 2017-05
Schedule of Equity Method Investments [Line Items]
Other long-term liabilities					$ 2,100,000
Investment in equity investee					3,000,000.0
Retained earnings					$ 900,000
Corporate Venture
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage	30.00%
Other long-term liabilities	$ 7,000,000.0
Deferred gain amortization period	5 years
Investment in equity investee		2,700,000	1,700,000
Impairment of investments		0	0	0
Cost of sales		61,900,000	52,200,000	$ 21,700,000
Accounts receivable		7,800,000	13,100,000
Corporate Venture | Investor In China
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage	70.00%
Corporate Venture | Accrued Liabilities
Schedule of Equity Method Investments [Line Items]
Unamortized deferred gain		2,000,000.0	2,000,000.0
Corporate Venture | Long-Term Liabilities
Schedule of Equity Method Investments [Line Items]
Unamortized deferred gain		$ 1,000,000.0	$ 3,000,000.0